Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 3/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 3/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20096278 | 1.00 | SCN9A (0.43) | SCN9APKMCNR2BCHECCR5 | |
| SCHEMBL20063434 | 0.86 | SCN9A (0.42) | SCN9APKMCNR2BCHECCR5 | |
| SCHEMBL20063427 | 0.85 | SCN9A (0.43) | SCN9APKMCNR2BCHECCR5 | |
| SCHEMBL4781528 | 0.76 | CCR5 (0.47) | PKMBCHECCR5ALDH1A1KMT2A | |
| SCHEMBL20096230 | 0.76 | CCR5 (0.47) | PKMBCHECCR5ALDH1A1KMT2A | |
| SCHEMBL20096210 | 0.76 | CCR5 (0.47) | PKMBCHECCR5ALDH1A1KMT2A | |
| SCHEMBL20072938 | 0.76 | SCN9A (0.40) | SCN9ACCR5MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20096287 | 0.76 | SCN9A (0.42) | SCN9AOPRK1 | |
| SCHEMBL20063416 | 0.75 | SCN9A (0.41) | SCN9ACCR5 | |
| SCHEMBL20095512 | 0.75 | SCN9A (0.35) | SCN9APKMCNR2BCHECCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10457654-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10457654-B2 | Therapeutic compounds and methods of use thereof | NPY5R, REN, F12 | SCN9A 1478/4885PKM 2488/4885CNR2 296/4885 |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NPY5R, REN, F12 | SCN9A 1501/4885PKM 2407/4885CNR2 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.